OmniAb, Inc. (NASDAQ: OABI) is a Healthcare company (Biotechnology) with a market capitalization of $737M. The Maz Rating grades it against the other companies in its sector.
OmniAb, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $5.05, OmniAb, Inc. trades at 18.1x sales and 2.6x book value. Over the last twelve months it generated about $41M of revenue and a net loss of $50M. It runs a gross margin of 63.6%, an operating margin of -115.8% and a net margin of -108.2%. It shows return on equity of -16.7%, return on invested capital of -16.4% and a free cash flow yield of 0.3%. On the balance sheet: a debt-to-equity ratio of 0.07 and a current ratio of 4.21. Over the past 52 weeks the share price ranged from $1.35 to $5.45, with a beta of 1.05.
OmniAb, Inc. does not currently pay a dividend.
11 Wall Street analyst ratings cover the stock: 11 Buy, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.